• +1-646-491-9876
    • +91-20-67278686

    Search

    Interleukin 1-Pipeline Review H1 2017

    Interleukin 1-Pipeline Review H1 2017

    • Report Code ID: RW0001834440
    • Category Pharmaceuticals
    • No. of Pages 99
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Interleukin 1 (IL1) - Pipeline Review, H1 2017

    Summary

    Interleukin 1 (IL1) pipeline Target constitutes close to 28 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Interleukin 1 (IL1) - Pipeline Review, H1 2017, outlays comprehensive information on the Interleukin 1 (IL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.

    Interleukin 1 (IL1) - Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of the brain that control body temperature. There are two forms of interleukin-1, alpha and beta. IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 9, 2, 11 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Dermatology, Musculoskeletal Disorders, Immunology, Metabolic Disorders, Cardiovascular, Oncology, Central Nervous System, Genetic Disorders, Ear Nose Throat Disorders, Gastrointestinal and Genito Urinary System And Sex Hormones which include indications Gouty Arthritis (Gout) , Acne Vulgaris, Epidermolysis Bullosa, Inflammation, Atherosclerosis, Behcet Disease, Familial Mediterranean Fever, Non-Small Cell Lung Cancer, Rheumatoid Arthritis, Type 2 Diabetes, Alzheimer's Disease, Autoimmune Disorders, Bladder Cancer, Cardiovascular Risk Factors, Colorectal Cancer, Dermatological Disorders, Diabetes, Esophageal Cancer, Fallopian Tube Cancer, Hearing Disorders, Hidradenitis Suppurativa, Hypercholesterolemia, Kidney Fibrosis, Liver Fibrosis, Lymphoma, Metastatic Colorectal Cancer, Mevalonate Kinase Deficiency (Hyperimmunoglobulin D Syndrome (HIDS) ) , Muckle-Wells Syndrome, Myocardial Infarction, Neonatal Onset Multisystem Inflammatory Disease, Osteoarthritis, Ovarian Cancer, Pain, Peripheral Arterial Disease (PAD) / Peripheral Vascular Disease (PVD) , Plaque Psoriasis (Psoriasis Vulgaris) , Prostate Cancer, Restenosis, Sarcoidosis, Skin Inflammation, Systemic Idiopathic Juvenile Arthritis and Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (Familial Hibernian Fever) .

    Furthermore, this report also reviewsalso reviews key players involved in Interleukin 1 (IL1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Interleukin 1 (IL1)
    - The report reviews Interleukin 1 (IL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Interleukin 1 (IL1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Interleukin 1 (IL1) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Interleukin 1 (IL1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Interleukin 1 (IL1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Interleukin 1 (IL1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Interleukin 1 (IL1) - Overview
    Interleukin 1 (IL1) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Interleukin 1 (IL1) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Interleukin 1 (IL1) - Companies Involved in Therapeutics Development
    AbbVie Inc
    Anacor Pharmaceuticals Inc
    Apexigen Inc
    Cell Medica Ltd
    Exicure Inc
    Immune Response BioPharma Inc
    Novartis AG
    Omnitura Therapeutics Inc
    Opsona Therapeutics Ltd
    Optimum Therapeutics LLC
    Orphit SAS
    Peptinov SAS
    R Pharm
    Regeneron Pharmaceuticals Inc
    Swedish Orphan Biovitrum AB
    TWi Biotechnology Inc
    XBiotech Inc
    Interleukin 1 (IL1) - Drug Profiles
    ABT-981 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AC-203 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AN-4161 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antisense Oligonucleotide to Inhibit IL-1 Beta for Epidermolysis Bullosa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    APX-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    canakinumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CV-18C3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    diacerein - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    diacerein CR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DLX-2323 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DLX-2681 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IR-1000 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IR-1002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IR-888 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MABp-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    melittin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OMN-54 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PPV-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RA-18C3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rilonacept - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RPH-104 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SOBI-006 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    suramin hexasodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    T-218C3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Xilonix - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Ymalzen - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Interleukin 1 (IL1) - Dormant Products
    Interleukin 1 (IL1) - Discontinued Products
    Interleukin 1 (IL1) - Product Development Milestones
    Featured News & Press Releases
    Jun 01, 2017: XBiotech Presents Phase III Findings for its Antibody Therapy for Colorectal Cancer at the 2017 ASCO Meeting
    May 30, 2017: Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Cancer
    Apr 20, 2017: XBiotech Announces Outcome of EMA's Oral Explanation Meeting
    Mar 06, 2017: Castle Creek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for Diacerein 1% Ointment in Treatment of Epidermolysis Bullosa Simplex
    Feb 22, 2017: XBiotech Completes Dosing of Subjects in PK Study Being Conducted in Connection with European Marketing Application
    Feb 21, 2017: Xbiotech Reports Affirmative Interim Analysis Of Global Phase 3 Colorectal Cancer Study
    Feb 16, 2017: XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa
    Jan 17, 2017: XBiotech Phase 3 Data for Colorectal Cancer Therapy is Published in The Lancet Oncology
    Dec 16, 2016: Novartis receives positive CHMP recommendation for Ilaris to treat rare diseases in adults and children called Periodic Fever Syndromes
    Dec 07, 2016: XBiotech Completes Enrollment in Global Phase III Study using Xilonix Monotherapy to Treat Advanced Colorectal Cancer
    Oct 12, 2016: Xbiotech Announces Successful Completion of EMA GMP Inspection
    Oct 01, 2016: Castle Creek Pharmaceuticals Announces Late-Breaking Results at EADV of Phase 2 Topical Diacerein 1% Data in Patients with Epidermolysis Bullosa Simplex
    Sep 23, 2016: Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions
    Jul 22, 2016: XBiotech Provides Update on Xilonix Phase III Programs in US and EU
    Jul 14, 2016: The Debate on the Phase 3 Trial of MABp1 Presented at the 18th ESMO World Congress of Gastrointestinal Cancer
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by AbbVie Inc, H1 2017
    Pipeline by Anacor Pharmaceuticals Inc, H1 2017
    Pipeline by Apexigen Inc, H1 2017
    Pipeline by Cell Medica Ltd, H1 2017
    Pipeline by Exicure Inc, H1 2017
    Pipeline by Immune Response BioPharma Inc, H1 2017
    Pipeline by Novartis AG, H1 2017
    Pipeline by Omnitura Therapeutics Inc, H1 2017
    Pipeline by Opsona Therapeutics Ltd, H1 2017
    Pipeline by Optimum Therapeutics LLC, H1 2017
    Pipeline by Orphit SAS, H1 2017
    Pipeline by Peptinov SAS, H1 2017
    Pipeline by R Pharm, H1 2017
    Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
    Pipeline by Swedish Orphan Biovitrum AB, H1 2017
    Pipeline by TWi Biotechnology Inc, H1 2017
    Pipeline by XBiotech Inc, H1 2017
    Dormant Products, H1 2017
    Dormant Products, H1 2017 (Contd..1) , H1 2017
    Dormant Products, H1 2017 (Contd..2) , H1 2017
    Dormant Products, H1 2017 (Contd..3) , H1 2017
    Dormant Products, H1 2017 (Contd..4) , H1 2017
    Discontinued Products, H1 2017
    Discontinued Products, H1 2017 (Contd..1) , H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AbbVie Inc
    Anacor Pharmaceuticals Inc
    Apexigen Inc
    Cell Medica Ltd
    Exicure Inc
    Immune Response BioPharma Inc
    Novartis AG
    Omnitura Therapeutics Inc
    Opsona Therapeutics Ltd
    Optimum Therapeutics LLC
    Orphit SAS
    Peptinov SAS
    R Pharm
    Regeneron Pharmaceuticals Inc
    Swedish Orphan Biovitrum AB
    TWi Biotechnology Inc
    XBiotech Inc

    Request for Sample

    Report Url https://www.reportsweb.com//interleukin-1-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//interleukin-1-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//interleukin-1-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments